• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effective clinical response of lung adenocarcinoma harboring 19Del/T790M/-C797S osimertinib to and combination therapy.

作者信息

Wang Yanyan, Jiang Chenchen, Tang Mingyue, Li Huiyuan, Zhao Cancan, Zhao Menglin, Zhang Yue, Li Xinwei, Mi Jiaqi, Shen Honghong, Wang Zishu, Su Fang

机构信息

Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.

Department of Internal Medicine, Foshan First People's Hospital, Foshan, China.

出版信息

Quant Imaging Med Surg. 2023 Aug 1;13(8):5362-5368. doi: 10.21037/qims-22-1269. Epub 2023 May 11.

DOI:10.21037/qims-22-1269
PMID:37581042
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10423355/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/10423355/c68ac5fca887/qims-13-08-5362-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/10423355/7c83b2f796d1/qims-13-08-5362-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/10423355/c68ac5fca887/qims-13-08-5362-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/10423355/7c83b2f796d1/qims-13-08-5362-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/10423355/c68ac5fca887/qims-13-08-5362-f2.jpg

相似文献

1
Effective clinical response of lung adenocarcinoma harboring 19Del/T790M/-C797S osimertinib to and combination therapy.携带19Del/T790M/-C797S的肺腺癌对奥希替尼及联合治疗的有效临床反应。
Quant Imaging Med Surg. 2023 Aug 1;13(8):5362-5368. doi: 10.21037/qims-22-1269. Epub 2023 May 11.
2
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.布加替尼与西妥昔单抗联合治疗携带有 EGFR 激活突变、T790M 和 cis-C797S 三重突变的肺腺癌的疗效。
J Thorac Oncol. 2020 Aug;15(8):1369-1375. doi: 10.1016/j.jtho.2020.04.014. Epub 2020 Apr 27.
3
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report.奥希替尼、贝伐单抗和布加替尼联合治疗携带L858R、T790M和-C797S三重EGFR突变的肺腺癌：一例报告
Onco Targets Ther. 2018 Sep 6;11:5545-5550. doi: 10.2147/OTT.S170358. eCollection 2018.
4
Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis T790M-C797S in NSCLC: A Case Report.奥希替尼与安罗替尼联合使用可能克服非小细胞肺癌中顺式T790M-C797S介导的耐药性：一例报告
Onco Targets Ther. 2021 Apr 28;14:2847-2851. doi: 10.2147/OTT.S298655. eCollection 2021.
5
Two case reports of non-small cell lung cancer patients harboring acquired T790M--C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy.两例携带获得性T790M-C797S的非小细胞肺癌患者受益于免疫检查点抑制剂联合铂类双药化疗的病例报告。
Ann Transl Med. 2022 Jun;10(12):719. doi: 10.21037/atm-22-2436.
6
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.奥希替尼耐药的 EGFR 突变型肺癌对第一代可逆性 EGFR 抑制剂敏感，但在临床前模型和临床样本中最终会获得 EGFR T790M/C797S 耐药突变。
J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: 10.1016/j.jtho.2019.07.016. Epub 2019 Aug 1.
7
Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.奥希替尼耐药的肺腺癌患者存在 EGFR T790M-cis-C797S 突变时，采用布加替尼为基础的治疗，或化疗联合抗血管生成治疗的可能性。
Cancer Med. 2021 Dec;10(23):8328-8337. doi: 10.1002/cam4.4336. Epub 2021 Oct 6.
8
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.奥希替尼与吉非替尼联合治疗 C797S 和 T790M 突变的非小细胞肺癌。
J Thorac Oncol. 2017 Nov;12(11):1728-1732. doi: 10.1016/j.jtho.2017.08.006. Epub 2017 Aug 24.
9
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.肺腺癌伴 EGFR T790M 和 in trans C797S 对第一代和第三代 EGFR TKI 联合治疗有反应，并在耐药时改变等位基因构型。
J Thorac Oncol. 2017 Nov;12(11):1723-1727. doi: 10.1016/j.jtho.2017.06.017. Epub 2017 Jun 27.
10
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, -G796s/-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report.奥希替尼、布加替尼和贝伐单抗联合治疗携带L858R、T790M、-G796s/-C797s三重表皮生长因子受体（EGFR）突变的肺腺癌：一例报告
Respir Med Case Rep. 2022 Jan 10;36:101582. doi: 10.1016/j.rmcr.2022.101582. eCollection 2022.

引用本文的文献

1
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.优化奥希替尼用于非小细胞肺癌的治疗：靶向耐药性并探索联合疗法。
Cancers (Basel). 2025 Jan 29;17(3):459. doi: 10.3390/cancers17030459.

本文引用的文献

1
Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.克服 C797S 突变：第四代 EGFR-TKIs 的挑战与展望。
Bioorg Chem. 2022 Nov;128:106057. doi: 10.1016/j.bioorg.2022.106057. Epub 2022 Aug 1.
2
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.非小细胞肺癌中 EGFR 外显子 20 插入与铂类化疗的反应。
Clin Lung Cancer. 2022 Mar;23(2):e148-e153. doi: 10.1016/j.cllc.2021.07.001. Epub 2021 Jul 19.
3
The ever-increasing importance of cancer as a leading cause of premature death worldwide.
癌症作为全球范围内导致过早死亡的主要原因，其重要性日益增加。
Cancer. 2021 Aug 15;127(16):3029-3030. doi: 10.1002/cncr.33587. Epub 2021 Jun 4.
4
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.表皮生长因子受体酪氨酸激酶抑制剂纪事：靶向含三重突变的表皮生长因子受体C797S
Biomol Ther (Seoul). 2022 Jan 1;30(1):19-27. doi: 10.4062/biomolther.2021.047.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
Mechanisms of osimertinib resistance and emerging treatment options.奥希替尼耐药机制及新出现的治疗选择。
Lung Cancer. 2020 Sep;147:123-129. doi: 10.1016/j.lungcan.2020.07.014. Epub 2020 Jul 18.
7
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.AURA3 试验中外周血和组织标本中表皮生长因子受体突变分析：奥希替尼对比培美曲塞/顺铂用于 T790M 突变阳性的晚期非小细胞肺癌。
Cancer. 2020 Jan 15;126(2):373-380. doi: 10.1002/cncr.32503. Epub 2019 Nov 26.
8
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.奥希替尼耐药的 EGFR 突变型肺癌对第一代可逆性 EGFR 抑制剂敏感，但在临床前模型和临床样本中最终会获得 EGFR T790M/C797S 耐药突变。
J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: 10.1016/j.jtho.2019.07.016. Epub 2019 Aug 1.
9
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.MET 抑制剂在 EGFR TKI 耐药肺癌的靶向治疗中的应用。
J Hematol Oncol. 2019 Jun 21;12(1):63. doi: 10.1186/s13045-019-0759-9.
10
Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.携带EGFR 19Del/T790M/反式C797S的肺腺癌对第一代和第三代EGFR酪氨酸激酶抑制剂联合治疗的持久临床反应
J Thorac Oncol. 2019 Aug;14(8):e157-e159. doi: 10.1016/j.jtho.2019.04.020. Epub 2019 May 7.